

Evento ECM RES
XIII ANNUAL MEETING ON PITUITARY TUMORS
UpToDate on PitNET
From basic research to clinical management
Roma, November 26th -27th
Hotel Donna Camilla Savelli

SEDE**Hotel Donna Camilla Savelli**

Via Garibaldi 27, 00153 Roma RM

Provider ECM e Segreteria Organizzativa**DOTCOM SRL Provider ECM ID 680**

Via Flaminia, 54 - 00196 Roma

Tel. 06 4061370 – Fax 06 3242600

E-Mail: info@dotcomeventi.com;**DESTINATARI**

Medico- Chirurgo: Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.

RESPONSABILI SCIENTIFICI**Prof.ssa Laura De Marinis**

Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo-ipofisarie / Università Cattolica del Sacro Cuore - Roma

Prof. Antonio Bianchi

Dirigente medico I livello U.O.S. di Patologie Ipotalamo-ipofisarie, Fondazione Policlinico Universitario A. Gemelli - IRCCS Roma

NUMERO PARTECIPANTI: 100**ORE FORMATIVE : 11****PROVENIENZA PARTECIPANTI: NAZIONALE****EVENTO ECM RES****PLURISPONSOR**

RATIONALE

Pituitary adenomas/PitNET represents a complex disease, with a wide spectrum of clinical manifestations, from small benign lesions to aggressive PitNET, according to the ability of secreting different hormones or pro-hormones or of invading the neighbouring anatomical structures and to treatment resistance. Macroadenomas can cause mass effect, consisting of visual field defects, headache or hypopituitarism. People with hypopituitarism due to pituitary adenomas have an approximately 2-fold increase in all-cause mortality compared with the general population. Some syndromes of pituitary hormone excess are also associated with excess all-cause mortality. Acromegaly was associated with a 2-fold increase in all-cause mortality rate in studies published before 2008, but not in more recently published studies or in the subgroups of patients who achieved biochemical control of the disease. Cushing disease has been associated with a 3-fold increase in all-cause mortality rate. Aggressive PitNETs (APTs) are a small subset, around 10 % of all PitNETs, defined as tumours which are radiologically invasive with unusually rapid tumour growth or clinically relevant tumour growth despite optimal standard therapies. Pituitary carcinomas (PCs) specifically denote APTs that have metastasised (craniospinal or systemic) and comprise up to 0.4 % of all PitNETs. Current guidelines for the management of APTs and PCs recommend treatment with surgery, radiotherapy and temozolomide; however by definition these tumours progress despite these therapies and treatment options beyond current recommendations are experimental. In this field, precision medicine management is a rapidly expanding area that enables delivery of molecular based personalised therapies, and this approach may improve outcomes for patients with PitNET. In the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments.

The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between neuroendocrinologist, ophthalmologist, pathologists, neurosurgeons, radiotherapist and nuclear medicine physician.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease - Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome.

XIII ANNUAL MEETING ON PITUITARY TUMORS**UpToDate on PitNET****From basic research to clinical management***Roma, November 26th -27th***Hotel Donna Camilla Savelli****1st Day - Thursday, November 26th 2026****12.00 "Bone" Session**

Bone fragility in Pituitary Diseases

Chairman: **A. Spada**Discussant: **S. Chiloiro, L. Di Filippo, S. Frara, E. Sbardella****13.00 welcome lunch****14.30 Introduction: L. De Marinis, A. Bianchi**

Welcome Speech:

A. Pontecorvi, D. Ferone, L. Festa, A. Lenzi, G. Reimondo, A. Sgambato, A. Spada, G. Fioroni, R. Baldelli**PRESIDENTIAL LECTURE**Chairmen: **A. Lenzi, A. Pontecorvi****15.00 Update sulla consensus per la gestione multidisciplinare dell'acromegalia
A. Giustina****I SESSION: New knowledges and acquisitions on PitNET**Chairman: **G. Mantovani, G. Rindi**Discussant: **M.L. Jaffrain-Rea****15.30 Controversies in pathology reporting of PitNET
M. Gessi, L. Poliani****16.10 LECTURE***Integration of molecular profiling in the diagnosis and prognostic stratification of PitNETs***F. Roncaroli****16.30 Epigenetics of Pituitary tumors****M. Puig Domingo**

16.50 *New drugs for the treatment of acromegaly*
F. Gatto

17.10 Personalizing radiotherapy for PitNETs: indications, timing and modern techniques
A. Martino, G. Minniti

17.40 Discussion

PRESIDENTIAL LECTURE

Chairmen: **V. Rufini, M. C. Zatelli**

18.00 Radiometabolic therapy in neuroendocrine tumors: the Italian Experience 2026
D. Ferone

18.30 Conclusions

2nd Day -Friday November 27th, 2026

08.30 Registration

09.00 PRESIDENTIAL LECTURE

Chairmen: **E. Ghigo, P. Zuppi**

A concept of Pituitary Tumours Centers of Excellence - PTCOE

F. Casanueva

II SESSION: The emerging aspects of Pituitary diseases

Chairmen: **S. Cannavò, G. Aimaretti**

Discussant: **A. Lania, G. Vitale, S. Grottoli**

09.30 Genetic obesities, new treatments and real-world experience
TBD

09.50 Lights and Shadows of rhGH therapy in the adult
V. Gasco, D. Cuboni

10.10 *Coffee Break*

III SESSION: Management of sellar and parasellar tumors

Chairmen: **E. Capoluongo, E. De Menis,**

Discussant: **L. Lauretti, M. Rigante, T. Tartaglione, M. Zollino**

10.30 Deleterious germline variants in cancer risk genes among patients with pituitary tumors: an emerging genetic landscape

G. L. Scaglione, G. Trivellin

11.00 Patient Perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society International patient Survey

N. Karavitaki

11.20 Surgical management of sellar and parasellar tumors: technical adjuncts and modern outcomes

F. Doglietto

11.40 News in radiological techniques of aggressive Pituitary Tumors

S. Gaudino

12.00 The contribution of Nuclear Medicine: when and why?

C. Caldarella

12.20 Discussion

12.50 *Light Lunch*

IV SESSION: Uptodate in Cushing's diseaseChairmen: **A. Bianchi, A. Isidori**Discussant: **C. Scaroni, M. Poggi**

14.00 The Chronobiology of Hormones: from biology to treatments
TBD

14.20 Peripheral blockers and central acting drugs in the treatment of Cushing's disease
C. Simeoli

14.40 Combination therapy for Cushing's disease
R. Pivonello

15.00 Real-life data on pasireotide in monotherapy or combined in active Cushing's disease
TBD

15.20 Discussion

LECTUREChairman: **S. Chiloiro, P. Maffei**

15.40 Are paediatric pituitary adenomas/PitNETs different from adult ones?
TBD

16.00 Discussion

Closing remarks